摘要
目的分析探讨子宫肌瘤患者行米非司酮治疗的临床价值。方法采用回顾性分析形式对我院于2018年1月-2019年1月期间所收治的54例子宫肌瘤患者进行研究,所有患者均予以米非司酮治疗,治疗前后均予以彩色超声检查测定指标。结果用药前子宫平均体积和最大肌瘤分别为(328.25±41.63)cm^3、(132.51±31.25)cm^3;用药后上述指标分别为(240.11±12.22)cm^3、(71.97±16.37)cm^3。组间对比差异有统计学意义(P<0.05);用药后FSH、LH、E2以及P的平均水平较比用药前有所降低(P<0.05),T和PRL用药前后差异无统计学意义(P>0.05),用药过程中尿常规和肝功能指标正常。结论米非司酮治疗子宫肌瘤的效果显著,不良反应小。
Objective To investigate the clinical value of mifepristone in the treatment of uterine leiomyoma.Methods 54 cases of uterine leiomyoma treated in our hospital from January 2018 to January 2019 were studied retrospectively.All patients were treated with mifepristonen and the indexes were measured by color ultrasound before and after treatment.Results The average uterine volume and the largest fibroids before treatment were(328.25±41.63)cm^3,(132.51±31.25)cm^3;the above indexes were(240.11±12.22)cm^3,and(71.97±16.37)cm^3,respectively.The contrast difference between the groups was statistically significant(P<0.05);the average levels of FSH,LH,E2,and P after administration were lower than those before administration(P<0.05),and there was no significant difference between T and PRL before and after administration(P>0.05),urine routine and liver function indexes were normal during medication.Conclusion Mifepristone is effective in the treatment of uterine leiomyoma with less adverse reactions.
作者
鲁林风
LU Linfeng(Department of Obstetrics and Gynecology,Jingmen Maternal and Child Health Hospital,Jingmen Hubei 448000,China)
出处
《中国继续医学教育》
2020年第6期132-134,共3页
China Continuing Medical Education
